Cross-sectional description of early postnatal fatty acid patterns in delivered preterm infants Authors: Chuan Zhang, Zhao Wang, Hui Wu, Lin Xie, Haitao Yu, Dan Dang Published: 2026 ABSTRACT SummaryPreterm birth prematurely interrupts maternal fatty acid supply, yet gestational age-specific serum fatty acid profiles and perinatal determinants remain incompletely defined. In this prospective cohort, serum samples of very preterm infants (<32 weeks) collected within 24 h of birth were analyzed by gas chromatography-mass spectrometry. Fatty acids were classified as SCFAs, MCFAs, LCFAs, MUFAs, and PUFAs. Associations with gestational age, maternal comorbidities, antenatal medications, and infant sex were assessed using multivariable linear regression. A total of 105 very preterm infants were included. Lower gestational age was associated with greater fatty acid insufficiency. Total SCFAs increased with gestational age (p = 0.003), driven by rising butyric acid (C4:0) and caproic acid (C6:0). SFAs and MUFAs increased significantly (p = 0.005 and 0.04) with gestational age. Although total LCFAs and PUFAs did not differ significantly, the proportion of linoleic acid increased with gestational age (C18:2n6c) (p = 0.01). Maternal hypertension was associated with higher proportions of C18:2n6c (p = 0.001) and decreased levels of eicosatrienoic acid (C20:3n6, p = 0.04) and arachidonic acid (ARA, C20:4n6; p = 0.05). Infants of diabetic mothers showed an elevated ARA/DHA (docosahexaenoic acid, C22:6n3) ratio (p = 0.003). In multiple gestation, the C18:2n6c proportion increased (p = 0.0007), and the DHA proportion decreased (p = 0.005). Male infants had lower levels and proportions of C20:3n6 than females (p = 0.009 and 0.003). Antenatal corticosteroids were associated with reduced levels and proportions of C6:0 (both p = 0.02), decreased C18:2n6c proportion (p = 0.003), and higher levels of ARA (p = 0.03) and DHA (p = 0.05). Antenatal magnesium sulfate exposure was linked to decreased levels and proportions of C16:1n7 (p = 0.04 and 0.05). Serum fatty acid profiles in preterm infants exhibit gestational age-dependent patterns and are associated with maternal comorbidities, antenatal medication exposure, and infant sex, providing new insights into early postnatal fatty acid status in this population. Introduction Sustaining extrauterine growth in preterm infants requires adequate nutritional support. Fatty acids function as both primary energy sources and structural elements of cellular membranes, while also regulating signaling, inflammation, and neurodevelopment.1,2,3,4 The premature interruption of placental fatty acid transfer in late gestation predisposes infants to deficiencies and metabolic dysregulation, which are considered potential contributors to impaired postnatal growth and an increased risk of morbidities such as bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and adverse neurodevelopmental outcomes.5,6,7,8 Although neonatal fatty acid metabolism is a research hotspot, current studies mainly focus on exogenous fatty acid interventions or the association between fatty acid levels and adverse disease outcomes. Baseline fatty acid profiles in neonates, particularly in preterm infants, remain poorly characterized. Only a limited number of studies have examined neonatal fatty acid composition: one compared fatty acid levels across gestational ages in term infants,9 while another analyzed erythrocyte membrane fatty acids in 30 preterm infants but only relative to 10 term controls,10 without systematic stratification across different preterm gestational age groups. Gestational age-specific analyses are therefore scarce. Moreover, most interventional studies have focused on individual fatty acids such as arachidonic acid (ARA, C20:4n6) and docosahexaenoic acid (DHA, C22:6n3), neglecting the overall balance among saturated, monounsaturated, and polyunsaturated fatty acids.11,12,13,14 In addition, the potential impact of maternal complications, perinatal medication exposure, and nutritional factors—conditions frequently encountered in preterm populations—has not been systematically assessed in relation to neonatal fatty acid metabolism. Comprehensive profiling of preterm-specific fatty acid metabolism, together with the assessment of perinatal influences, is therefore essential to delineate distinctive metabolic signatures and to inform individualized nutritional strategies aimed at improving long-term outcomes. Results Baseline characteristics of the study population A total of 105 very preterm infants with a gestational age of <32 weeks were enrolled in this study (Figure 1), comprising 24 infants in the <28 weeks group, 37 in the 28–30 weeks group, and 44 in the ≥30 weeks group. The overall mean gestational age was 29.2 ± 1.8 weeks, and the mean birth weight was 1.2 ± 0.3 kg. No significant difference was observed in sex distribution among the three groups.Figure 1Flow chart of study population. Flow chart of study population. The incidences of respiratory distress syndrome (RDS, 89.5%), BPD (53.3%), and ROP (35.2%) increased significantly with decreasing gestational age, whereas the rates of NEC, PDA, IVH, and PVL did not differ significantly among groups. Mortality occurred exclusively in the <28 weeks group. The length of hospital stay decreased significantly with increasing gestational age. Maternal complications during pregnancy, including diabetes and hypertension, showed no significant differences among groups (Table 1).Table 1Baseline characteristics of the study populationCharacteristicsTotal (n = 105)Gestational age<28 weeks (n = 24)Gestational age28–30 weeks (n = 37)Gestational age30–32 (n = 44)Male sex (n, %)55 (52.4)14 (58.3)19 (51.4)22 (50.0)Gestational age (week) (mean ± SD)29.2 (1.8)26.7 (1.2)28.7 (0.5)30.8 (0.7)Birth weight (kg) (mean ± SD)1.2 (0.3)0.9 (0.2)1.2 (0.3)1.5 (0.3)Maternal age (years) (mean ± SD)32.7 (4.0)34.0 (4.3)32.7 (3.9)32.0 (3.8)IDM (n, %)32 (30.5)7 (29.2)12 (32.4)13 (29.5)HIP (n, %)23 (21.9)3 (12.5)11 (29.7)9 (20.5)C-section (n, %)54 (51.4)3 (12.5)21 (56.8)30 (68.2)Multiple birth (n, %)29 (27.6)5 (20.8)6 (16.2)18 (40.9)AC (n, %)17 (16.2)21 (87.5)30 (81.1)37 (84.1)AS (n, %)40 (38.1)14 (58.3)27 (73.0)24 (54.5)Apgar score@ 5 min < 5 (mean ± SD)6 (5.7)3 (12.5)1 (2.7)2 (4.5)PDA (n, %)33 (31.4)10 (41.7)11 (29.7)12 (27.3)ROP (n, %)37 (35.2)19 (79.2)17 (45.9)1 (2.3)RDS (n, %)94 (89.5)24 (100.0)36 (97.3)34 (77.3)BPD (n, %)56 (53.3)18 (75.0)17 (45.9)14 (31.8)IVH (n, %)39 (37.1)12 (50.0)10 (27.0)17 (38.6)NEC (n, %)3 (2.9)0 (0.0)1 (2.7)2 (4.5)PVL (n, %)1 (1.0)1 (4.2)0 (0.0)0 (0.0)Death (n, %)2 (1.9)2 (8.3)0 (0.0)0 (0.0)Hospitalization days (day) (mean ± SD)52.6 (23.0)72.7 (29.1)56.4 (11.8)38.4 (16.2)WBC (×109/L) (mean ± SD)10.9 (8.8)14.2 (12.1)10.4 (7.4)9.7 (7.3)Hb (g/L) (mean ± SD)153.8 (23.7)140.7 (21.0)160.2 (24.3)155.6 (22.3)PLT (×109/L) (mean ± SD)227.3 (61.6)249.6 (75.1)222.7 (61.6)219.1 (51.2)IDM, maternal diabetes; HIP, maternal hypertension; AC, antenatal corticosteroids; AS, antenatal magnesium sulfate; PDA, patent ductus arteriosus; ROP, retinopathy of prematurity; RDS, respiratory distress syndrome; BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; WBC, white blood cell count; Hb, hemoglobin; PLT, platelet count. Table 1Baseline characteristics of the study populationCharacteristicsTotal (n = 105)Gestational age<28 weeks (n = 24)Gestational age28–30 weeks (n = 37)Gestational age30–32 (n = 44)Male sex (n, %)55 (52.4)14 (58.3)19 (51.4)22 (50.0)Gestational age (week) (mean ± SD)29.2 (1.8)26.7 (1.2)28.7 (0.5)30.8 (0.7)Birth weight (kg) (mean ± SD)1.2 (0.3)0.9 (0.2)1.2 (0.3)1.5 (0.3)Maternal age (years) (mean ± SD)32.7 (4.0)34.0 (4.3)32.7 (3.9)32.0 (3.8)IDM (n, %)32 (30.5)7 (29.2)12 (32.4)13 (29.5)HIP (n, %)23 (21.9)3 (12.5)11 (29.7)9 (20.5)C-section (n, %)54 (51.4)3 (12.5)21 (56.8)30 (68.2)Multiple birth (n, %)29 (27.6)5 (20.8)6 (16.2)18 (40.9)AC (n, %)17 (16.2)21 (87.5)30 (81.1)37 (84.1)AS (n, %)40 (38.1)14 (58.3)27 (73.0)24 (54.5)Apgar score@ 5 min < 5 (mean ± SD)6 (5.7)3 (12.5)1 (2.7)2 (4.5)PDA (n, %)33 (31.4)10 (41.7)11 (29.7)12 (27.3)ROP (n, %)37 (35.2)19 (79.2)17 (45.9)1 (2.3)RDS (n, %)94 (89.5)24 (100.0)36 (97.3)34 (77.3)BPD (n, %)56 (53.3)18 (75.0)17 (45.9)14 (31.8)IVH (n, %)39 (37.1)12 (50.0)10 (27.0)17 (38.6)NEC (n, %)3 (2.9)0 (0.0)1 (2.7)2 (4.5)PVL (n, %)1 (1.0)1 (4.2)0 (0.0)0 (0.0)Death (n, %)2 (1.9)2 (8.3)0 (0.0)0 (0.0)Hospitalization days (day) (mean ± SD)52.6 (23.0)72.7 (29.1)56.4 (11.8)38.4 (16.2)WBC (×109/L) (mean ± SD)10.9 (8.8)14.2 (12.1)10.4 (7.4)9.7 (7.3)Hb (g/L) (mean ± SD)153.8 (23.7)140.7 (21.0)160.2 (24.3)155.6 (22.3)PLT (×109/L) (mean ± SD)227.3 (61.6)249.6 (75.1)222.7 (61.6)219.1 (51.2)IDM, maternal diabetes; HIP, maternal hypertension; AC, antenatal corticosteroids; AS, antenatal magnesium sulfate; PDA, patent ductus arteriosus; ROP, retinopathy of prematurity; RDS, respiratory distress syndrome; BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; WBC, white blood cell count; Hb, hemoglobin; PLT, platelet count. Baseline characteristics of the study population IDM, maternal diabetes; HIP, maternal hypertension; AC, antenatal corticosteroids; AS, antenatal magnesium sulfate; PDA, patent ductus arteriosus; ROP, retinopathy of prematurity; RDS, respiratory distress syndrome; BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; WBC, white blood cell count; Hb, hemoglobin; PLT, platelet count. Fatty acid composition across gestational age groups Marked differences in fatty acid composition were observed across gestational age groups (Figure 2; Table S1). Total SCFAs increased with advancing gestational age (p = 0.003), with significant elevations in butyric acid (C4:0) and its relative proportion (both p = 0.004), as well as caproic acid (C6:0) and its proportion (p = 0.001 and 0.02). Total MCFAs and LCFAs did not differ significantly among groups; however, total SFAs increased with gestational age (p = 0.005). Within this class, palmitic acid (C16:0) peaked in the 28–30 weeks group (p = 0.06).Figure 2Fatty acid composition across gestational age groupsC4:0, butyric acid; C6:0, caproic acid; C16:1n7, palmitoleic acid; C18:1n9c, oleic acid; C18:2n6c, linoleic acid; C20:4n6, arachidonic acid (ARA); FAs, fatty acids; SCFAs, short-chain fatty acids; SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; LCFAs, long-chain fatty acids; PUFAs, polyunsaturated fatty acids. Fatty acid composition across gestational age groups C4:0, butyric acid; C6:0, caproic acid; C16:1n7, palmitoleic acid; C18:1n9c, oleic acid; C18:2n6c, linoleic acid; C20:4n6, arachidonic acid (ARA); FAs, fatty acids; SCFAs, short-chain fatty acids; SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; LCFAs, long-chain fatty acids; PUFAs, polyunsaturated fatty acids. Total MUFAs increased with gestational age (p = 0.04), with significant elevations in oleic acid (C18:1n9c) and palmitoleic acid (C16:1n7) (p = 0.05 and 0.003). Although total PUFAs did not differ significantly (p = 0.4), linoleic acid (C18:2n6c) increased with gestational age (p = 0.01). Levels of ARA and DHA were comparable among groups; however, the proportion of ARA was significantly higher in the <28 weeks group (p < 0.001). Overall, total fatty acid concentrations tended to increase with gestational age, with a near-significant difference (p = 0.08). Perinatal factors influencing fatty acid composition in preterm infants Several perinatal factors were found to influence the fatty acid profiles of preterm infants (Table 2; Tables S2 and S3). Maternal hypertension had a selective but significant impact on specific n-6 PUFAs, primarily reflected by an increased proportion of C18:2n6c (p = 0.001) and lower levels of eicosatrienoic acid (C20:3n6; p = 0.04) and ARA (p = 0.05). Infants of diabetic mothers exhibited an elevated ARA/DHA ratio (p = 0.003).Table 2Perinatal factors influencing fatty acid composition in preterm infantsEstimateStd.error95% CIPHIPC18:2n6c ratio1.820.550.73–2.910.001C20:3n6−2.581.25−5.06–0.110.04C20:4n6−11.495.84−23.08–0.100.05IDMARA/DHA ratio0.240.110.02–0.460.03SEXC20:3n6−2.751.00−4.73–0.770.009C20:3n6ratio−0.560.19−0.94–0.190.003Multiple birthC18:2n6c ratio1.840.520.81–2.870.0007C22:6n3−7.082.85−12.7–1.430.02C22:6n3 ratio−1.430.50−2.42–0.430.005ACC6:0−0.400.16−0.72–−0.080.02C6:0ratio−0.160.06−0.30–0.040.02C18:2n6c ratio−1.990.64−3.27–0.710.003C20:4n615.36.81.64–28.970.03C22:6n37.013.530.0003–14.020.05ASC16:1n7−0.670.32−1.32–0.020.04C16:1n7ratio−0.160.08−0.33–0.0030.05Confounding adjustment: HIP was adjusted for gestational age, IDM, AC, AS, sex, and multiple birth. IDM was adjusted for gestational age, HIP, AC, AS, sex, and multiple birth. SEX was adjusted for gestational age, HIP, IDM, AC, AS, and multiple birth. Multiple birth was adjusted for gestational age, HIP, IDM, AC, AS, and sex. AC was adjusted for gestational age, HIP, IDM, sex, AS, and multiple birth. AS was adjusted for gestational age, HIP, IDM, sex, AC, and multiple birth.IDM, Maternal diabetes; HIP, Maternal hypertension; AC, Antenatal Corticosteroids; AS, Antenatal Magnesium Sulfate; C6:0, caproic acid; C16:1n7, palmitoleic acid; C18:2n6c, linoleic acid; C20:3n6, dihomo-gamma-linolenic acid (DGLA); C22:6n3, docosahexaenoic acid (DHA); ARA/DHA ratio, ratio of arachidonic acid to docosahexaenoic acid. Table 2Perinatal factors influencing fatty acid composition in preterm infantsEstimateStd.error95% CIPHIPC18:2n6c ratio1.820.550.73–2.910.001C20:3n6−2.581.25−5.06–0.110.04C20:4n6−11.495.84−23.08–0.100.05IDMARA/DHA ratio0.240.110.02–0.460.03SEXC20:3n6−2.751.00−4.73–0.770.009C20:3n6ratio−0.560.19−0.94–0.190.003Multiple birthC18:2n6c ratio1.840.520.81–2.870.0007C22:6n3−7.082.85−12.7–1.430.02C22:6n3 ratio−1.430.50−2.42–0.430.005ACC6:0−0.400.16−0.72–−0.080.02C6:0ratio−0.160.06−0.30–0.040.02C18:2n6c ratio−1.990.64−3.27–0.710.003C20:4n615.36.81.64–28.970.03C22:6n37.013.530.0003–14.020.05ASC16:1n7−0.670.32−1.32–0.020.04C16:1n7ratio−0.160.08−0.33–0.0030.05Confounding adjustment: HIP was adjusted for gestational age, IDM, AC, AS, sex, and multiple birth. IDM was adjusted for gestational age, HIP, AC, AS, sex, and multiple birth. SEX was adjusted for gestational age, HIP, IDM, AC, AS, and multiple birth. Multiple birth was adjusted for gestational age, HIP, IDM, AC, AS, and sex. AC was adjusted for gestational age, HIP, IDM, sex, AS, and multiple birth. AS was adjusted for gestational age, HIP, IDM, sex, AC, and multiple birth.IDM, Maternal diabetes; HIP, Maternal hypertension; AC, Antenatal Corticosteroids; AS, Antenatal Magnesium Sulfate; C6:0, caproic acid; C16:1n7, palmitoleic acid; C18:2n6c, linoleic acid; C20:3n6, dihomo-gamma-linolenic acid (DGLA); C22:6n3, docosahexaenoic acid (DHA); ARA/DHA ratio, ratio of arachidonic acid to docosahexaenoic acid. Perinatal factors influencing fatty acid composition in preterm infants Confounding adjustment: HIP was adjusted for gestational age, IDM, AC, AS, sex, and multiple birth. IDM was adjusted for gestational age, HIP, AC, AS, sex, and multiple birth. SEX was adjusted for gestational age, HIP, IDM, AC, AS, and multiple birth. Multiple birth was adjusted for gestational age, HIP, IDM, AC, AS, and sex. AC was adjusted for gestational age, HIP, IDM, sex, AS, and multiple birth. AS was adjusted for gestational age, HIP, IDM, sex, AC, and multiple birth. IDM, Maternal diabetes; HIP, Maternal hypertension; AC, Antenatal Corticosteroids; AS, Antenatal Magnesium Sulfate; C6:0, caproic acid; C16:1n7, palmitoleic acid; C18:2n6c, linoleic acid; C20:3n6, dihomo-gamma-linolenic acid (DGLA); C22:6n3, docosahexaenoic acid (DHA); ARA/DHA ratio, ratio of arachidonic acid to docosahexaenoic acid. Multiple gestation demonstrated selective and directionally consistent alterations in fatty acid composition after adjustment for gestational age and other confounders, with a significantly higher proportion of C18:2n6c (p = 0.0007) and a markedly lower proportion of DHA (p = 0.005). With respect to sex differences, male preterm infants had lower absolute levels and proportions of eicosatrienoic acid (C20:3n6) than females (p = 0.009 and 0.003, respectively), while no significant sex-related differences were noted for other fatty acids. Antenatal corticosteroid administration was associated with significant reductions in C6:0 and its proportion (both p = 0.02), as well as in the proportion of C18:2n6c (p = 0.003), and increased levels of ARA (p = 0.03) and DHA (p = 0.05). Exposure to antenatal magnesium sulfate was also associated with decreased levels and proportions of C16:1n7 (p = 0.04 and 0.05, respectively). Discussion This study systematically characterized serum fatty acid profiles in preterm infants with a gestational age <32 weeks and examined their associations with perinatal factors. Our findings revealed significant differences in fatty acid composition among preterm infants of varying gestational ages, with levels of SCFAs, SFAs, and MUFAs increasing markedly with advancing gestation. Additionally, maternal comorbidities, antenatal medications, and infant sex influenced fatty acid profiles, indicating that both gestational age and perinatal environment play key roles in modulating fatty acid metabolism in preterm infants. Although neonatal fatty acid metabolism has been a research focus, most existing studies have concentrated on the relationship between fatty acid profiles and adverse neonatal outcomes. In many of these studies, the measured fatty acid levels were largely influenced by exogenous interventions, such as lipid emulsions with different fatty acid compositions or enteral supplementation with long-chain fatty acids (e.g., DHA and ARA).15,16 Additionally, some studies have evaluated changes in breast milk fatty acid levels following such interventions,17 while others have focused on the LCFA profiles of preterm infants born to mothers with preeclampsia.18 A subset of studies has further examined the associations between maternal-fetal fatty acid status and adverse outcomes in preterm infants.7,19,20 Physiologically, an increase in fatty acid levels with advancing gestational age is expected. In our cohort, the trend approached significance. Limited attention has been given to the fatty acid status itself, particularly with respect to gestational age-dependent differences. Notably, one study comparing erythrocyte fatty acid composition between 30 preterm and 10 term infants found that preterm infants had significantly higher levels of SFAs and n-6 PUFAs, but lower levels of MUFAs and n-3 PUFAs at birth compared with term infants.10 Our study found that total long-chain and polyunsaturated fatty acids did not differ significantly across gestational age groups, whereas the proportion of linoleic acid increased with advancing gestational age. This pattern may be partly explained by the selective transport and metabolic regulation of fatty acids in the placenta. Transport-related proteins such as FATPs, FABPs, and LPL exhibit dynamic expression across gestation and may contribute to differential fatty acid distribution in the fetus.21 In addition, placental desaturases (e.g., FADS1 and FADS2) are involved in the conversion of linoleic acid into longer-chain n-6 PUFAs, and variations in their activity may influence the balance between linoleic acid and its downstream metabolites.22,23 These mechanisms may help maintain overall long-chain PUFA stability while allowing shifts in linoleic acid proportion. Maternal supply of fatty acids to the fetus is tightly regulated to support rapid neural and tissue development during late gestation.24 Although the infants in this study were delivered prior to late gestation, they still exhibited a gestational age-dependent upward trend in fatty acid levels. Preterm birth interrupts this critical placental transfer, rendering extremely preterm infants particularly susceptible to multiple fatty acid deficiencies. Fatty acids such as DHA and ARA are essential for neurodevelopment, immune regulation, and intestinal integrity; their reduced levels in preterm infants have been closely associated with complications including impaired brain development, NEC, BPD, and ROP.11,12,13 Consequently, the lower fatty acid levels observed in extremely preterm infants are biologically plausible and consistent with evidence linking fatty acid imbalance to adverse neonatal outcomes. Nevertheless, the lower levels of SCFAs, SFAs, and MUFAs observed in infants of lower gestational age may reflect either pathological deficiency or a physiological characteristic of extreme prematurity. Further cohort studies focusing on clinical outcomes, together with comparative analyses including healthy term neonates as references for fatty acid levels, are warranted to clarify this distinction. Preferential maternal-fetal transfer of LCFAs during late gestation is vital for optimal brain development. Maternal physiological conditions, including hypertension, diabetes, and multiple gestations, can alter lipid metabolism and thereby influence fatty acid transport and metabolism between mother and fetus.25,26 Our study found that maternal hypertension and diabetes were associated with alterations in fatty acid levels in preterm infants. However, detailed information on maternal dietary intake and early neonatal nutritional exposures, which may also affect infant serum fatty acid levels, was not available. In addition, the relatively limited sample size may have constrained the statistical power to detect weaker associations. Therefore, larger prospective studies with comprehensive assessments of maternal and neonatal nutrition and metabolic factors are warranted to further validate our findings. A limited but significant sex-specific difference was observed for C20:3n6 after univariate analyses, including gestational age, maternal hypertension, maternal diabetes, antenatal corticosteroids, antenatal magnesium sulfate, and multiple births, suggesting potential sex-dependent regulation of fatty acid metabolism, possibly mediated by hormonal influences on fatty acid synthesis and catabolism.27 Extremely preterm infants generally display lower fatty acid levels and a heightened risk of adverse morbidities, as confirmed by our findings, emphasizing the critical importance of appropriate fatty acid supplementation. Given the widespread insufficiency of fatty acids in preterm infants—especially among extremely and very preterm populations—nutritional interventions should focus on the adequate and balanced provision of SCFAs, MCFAs, and LCFAs. Supplementation strategies should be individualized based on gestational age and further tailored according to maternal comorbidities and antenatal medication exposure. Compared with single fatty acid supplementation, interventions aimed at optimizing the overall fatty acid profile are likely to better support energy metabolism, immune modulation, and organ development, providing more comprehensive protection and developmental benefits for preterm infants. Conclusively, in preterm infants with a gestational age below 32 weeks, serum fatty acid profiles exhibit a clear gestational age-dependent pattern. Maternal hypertension or diabetes, antenatal medications, and infant sex were significantly associated with specific fatty acid levels, indicating correlations between perinatal factors and fatty acid metabolism. These findings reveal gestational age-dependent differences in fatty acid profiles and the modulatory effects of maternal and perinatal factors, offering insights for future studies on fatty acid metabolism in preterm infants. Limitations of the study Several limitations of this study should be acknowledged, and the findings interpreted with caution. First, the present results cannot determine whether the lower fatty acid levels observed in extremely preterm infants reflect pathological deficiency or a physiological characteristic of extreme prematurity. Further cohort studies examining clinical outcomes, as well as comparative analyses including healthy term neonates as references for fatty acid levels, are needed to clarify this issue. Second, detailed information on maternal dietary intake and early neonatal nutritional exposures, which may also influence infant fatty acid levels, was not available. The absence of these data as potential confounders may have limited the ability to fully evaluate the effects of maternal comorbidities and infant sex on fatty acid profiles. In addition, common metabolic-related factors such as maternal gestational obesity, hyperlipidemia, smoking, alcohol consumption, and blood glucose were not considered, and the dose-response relationship between antenatal medication use and fatty acid profiles could not be assessed. Thirdly, although the sample size is relatively large compared with similar studies, the single-center design may limit generalizability. Moreover, only early postnatal fatty acid levels were assessed, and the effects of long-term nutritional interventions on fatty acid profiles and clinical outcomes were not examined. Finally, measurements were confined to plasma fatty acids without the assessment of red blood cell membranes or tissue levels, potentially underestimating certain metabolic features. Future studies should adopt multicenter, large-scale longitudinal cohorts to dynamically monitor fatty acid profiles over time and investigate their associations with growth, development, and disease outcomes. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, DD (dangdan@jlu.edu.cn; Address: No.1 Xinmin Street, Changchun, Jilin Province, China; Telephone: +86–13894822116; ORCID: 0000-0001-5058-417X). Materials availability This study did not generate new unique reagents. Data and code availability •The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files.•This paper does not report original code.•Other items: Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. •The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files. The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files. •This paper does not report original code. This paper does not report original code. •Other items: Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Other items: Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.